OncoMatch/Clinical Trials/NCT05019703
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
Is NCT05019703 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Atezolizumab and Cabozantinib for locally advanced osteosarcoma.
Treatment: Atezolizumab · Cabozantinib — This phase II trial studies the effect of atezolizumab and cabozantinib in treating adolescents and young adults with osteosarcoma that has come back (recurrent) or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab and cabozantinib may help to control the osteosarcoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Osteosarcoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: conventional osteosarcoma chemotherapy (cisplatin, doxorubicin, methotrexate, ifosfamide)
relapsed or become refractory to conventional therapy including some combination of cisplatin, doxorubicin, methotrexate, and/or ifosfamide
Cannot have received: cabozantinib (cabozantinib)
Prior treatment with cabozantinib
Cannot have received: immune checkpoint blockade combined with VEGF-targeted TKI
Exception: prior anti-PD-1, anti-PD-L1, with or without anti-CTLA-4 antibodies allowed
Prior treatment with immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies if given in combination with a VEGF-targeted tyrosine kinase inhibitor (TKI). Patients receiving prior anti-PD-1, anti-PD-L1, with or without anti-CTLA-4 antibodies will not be excluded
Lab requirements
Blood counts
ANC >= 1.0 x 10^9/L; lymphocyte count >= 0.5 x 10^9/L; platelet count >= 100 x 10^9/L; hemoglobin >= 90 g/L (may be transfused)
Kidney function
Creatinine clearance >= 50 mL/min (adults) or >= 50 mL/min/1.73m^2 (pediatrics 12-17); UPCR <= 1 mg/mg or 24h urine protein <= 1 g
Liver function
AST, ALT <= 3 x ULN for age; ALP <= 3 x ULN (<= 5 x ULN if bone metastases); serum bilirubin <= 1.5 x ULN (<= 3 x ULN if Gilbert disease)
Absolute neutrophil count (ANC) >= 1.0 x 10^9/L; Lymphocyte count >= 0.5 x 10^9/L; Platelet count >= 100 x 10^9/L; Hemoglobin >= 90 g/L; AST, ALT <= 3 x ULN; Alkaline phosphatase (ALP) <= 3 x ULN (<= 5 x ULN with bone metastases); Serum bilirubin <= 1.5 x ULN (<= 3 x ULN with Gilbert disease); Creatinine clearance >= 50 mL/min (adults) or >= 50 mL/min/1.73m^2 (pediatrics); Urine protein/creatinine ratio (UPCR) <= 1 mg/mg; Serum albumin >= 20 g/L
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify